<SEC-DOCUMENT>0001193125-17-291940.txt : 20170925
<SEC-HEADER>0001193125-17-291940.hdr.sgml : 20170925
<ACCEPTANCE-DATETIME>20170925061039
ACCESSION NUMBER:		0001193125-17-291940
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170925
FILED AS OF DATE:		20170925
DATE AS OF CHANGE:		20170925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		171098557

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d458540d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of September, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 5, 20 George Street, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 25 September 2017 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g458540txpg3a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">483 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr James Garner</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25 SEPTEMBER 2017</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GDC-0084 PROGRESS UPDATE: PHASE II STUDY REMAINS ON TRACK TO START BY
END OF 2017 AFTER FDA CONSULTATION</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, 25&nbsp;September 2017
&#150; Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in
October 2016, after it had completed a phase I clinical trial in advanced glioma. Novogen is taking GDC-0084 into a phase II clinical trial in the treatment of glioblastoma multiforme (GBM).</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Key Highlights</U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Highly constructive
meeting held with US Food and Drug Administration (FDA) on 21&nbsp;September in relation to the proposed phase II clinical study of GDC-0084; key features of study design remain substantially as proposed</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Phase II study in
adult GBM patients remains on track to launch before the end of 2017</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Independently of FDA feedback, study design has been refined to include a lead-in
component which aims to optimize dosing in the target population, leading to an earlier preliminary data read-out approximately <FONT STYLE="white-space:nowrap">12-15</FONT> months after commencement, and substantial de-risking of the overall
program</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Letter
of Intent (LOI) signed with Chiltern Oncology, a leading international contract research organization, as part of study initiation activity</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen CEO, Dr James Garner, commented on recent progress, &#147;We are grateful to FDA for their careful evaluation and considered advice and we are
encouraged by their engagement with the program. The study remains on track for commencement by the end of calendar 2017, and we are confident that our approach is optimized for success.&#148;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Outcome of FDA Consultation</U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Novogen conducted a Type B meeting with FDA on Thursday 21<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> September at the FDA&#146;s Center for Drug Evaluation and Research in Maryland, in order to discuss the proposed clinical development plan for <FONT STYLE="white-space:nowrap">GDC-0084</FONT> in
adult patients with GBM.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g458540txpg3b.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g458540tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is anticipated that written minutes of the meeting will be received in due course. However, Novogen is
confident following the meeting that the study remains on schedule to commence by the end of calendar 2017, and that the key design features remain substantially unchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen looks forward to working with the FDA, and with the clinician community, throughout this development program in order to rapidly understand the
potential benefit of GDC-0084 for patients with GBM. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Study Design Refined to Accommodate Lead-In Dose Optimisation Component </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Independently of FDA feedback, and in consultation with its clinician advisors, Novogen has elected to include a lead-in component in the phase II study that
will seek to optimize dosing in the intended patient population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phase I study conducted by Genentech was performed in patients with high-grade
gliomas (WHO Grade III-IV), including glioblastoma, and all patients had progressed during or after treatment with at least one prior line of therapy. Novogen intends to conduct the phase II study only in patients with glioblastoma, and in a
first-line setting, so it considers that there may be potential to deliver a higher dose or to improve the dosing regimen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The staged approach, with the
inclusion of a lead-in component, will help to substantially de-risk the overall phase II program, and will provide an initial data read-out approximately <FONT STYLE="white-space:nowrap">12-15</FONT> months after commencement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Letter of Intent Signed with Chiltern Oncology </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen
announced in August 2017 that it had entered into a Master Services Agreement (MSA) with Chiltern Oncology, a leading international Contract Research Organization (CRO). Further to that MSA, Novogen has now signed a Letter of Intent (LOI) with
Chiltern Oncology, which provides for initiation of set-up activities for the study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the GDC-0084 development candidate </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GDC-0084 is a
small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is distinguished from other molecules in the class by its ability to penetrate the blood-brain barrier. PI3K inhibitors have shown evidence of clinical activity in a broad range of
tumor types, and one product in the class has reached market for several hematological malignancies. GDC-0084 was developed by Genentech, who completed a phase I study in patients with recurrent glioma, and was licensed to Novogen in October 2016. A
phase II clinical trial is slated to begin in the fourth quarter of calendar 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of
development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best- in-class agents in a range of oncology indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g458540tx_pg04.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g458540tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead program is GDC-0084, a small molecule inhibitor of the PI3K&nbsp;/&nbsp;AKT&nbsp;/&nbsp;mTOR
pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. A second clinical program, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRX-E-002-01</FONT></FONT></FONT> (Cantrixil) commenced a phase&nbsp;I clinical trial in ovarian cancer in December 2016. In addition, the company has several preclinical programs in active
development, the largest of which is substantially funded by a <FONT STYLE="white-space:nowrap">CRC-P</FONT> grant from the Australian Federal Government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit: <U>www.novogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g458540tx_pg04.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g458540tx_pg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g458540tx_pg04.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  ^ L8# 1$  A$! Q$!_\0 R@ !  $% 0$! 0            4! P0&!P@"
M"0H! 0 " P$! 0             $!0$#!@('"!   0,#  8' 0D+"P('
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M+6X8)(9HS5CV'I'2"#H(.D'0=*@RBXO=EHT=):NV[UM7;34K<EHT9"P>P@"
M(#:\,"+(DBF]*_=ZQ1FD=50@)5 $ 0! $ 0! $ 0! $ 0$9DM4/:_P!YJ BD
M 0! $!\N>UNL^YK/<@+1G'WK3[J MF9YZ0.P>=4"VG'<@QC,CD',8QCG7MRY
MQ:UK2YSI7DN<0 7$D]*F1;<57F.9O1BLFY1)>\_68B]'D("(S_\ L>6_R$_Y
M*V6OS(_>(>?^BO?[;//RMCA@@" ( @" ( @" ( @" J"1J)'84!$9' 83+M+
M<GB<??5T[T]M&Z4':V=H;,T]C@MD+ERWX)->DBY&!A9?ZFU;G7G2KV[>\Y]D
M_1WE2]#G63LAB)' T%O<>TVX.G]C=B5]#U2!289]^/BI)=/[BAR?*7#+U79=
MRU+H=5V2J^\_0+DS$.QO)W*M@R9LXLN7</:B1S>$Z006$$>^65>&EP;6E32J
MYB_/?R+D^5S;[74^Z<(QGC<*QK*>]N8]N-=E:12K0GGM<P[KA0]%=1&T'45J
M+!Z.CVGR@-BPWZB;Z5OY"TW/%Z"58\+ZR77@WA 2>*_Q/]!WO(#94 0%1J/9
M]T( =9[3[Z H@" ( @" ( @" J 34@&@TD] &TG4 @-9O.=.3L?=-L;_ )MY
M9L[USMQMI<YW%PW&]JW3$^Z#FNKT&BVJQ>DJJ$FNID"[Q3AEBY\*]DX\+KY'
M<@GV-D[Q8KFSEGMI8KF!]O,63V\L<\+@8G4+98G/C<#U%:Z-2H]'4EN49V7.
M#4H.+U3JMG.CQ-YE7Y\MCL"&0@*(".GQ=K,2[==$XU),9H"3K):06Z>JB CI
M<)(*F*9KM@>TM-.T;PJLC4CY<?=Q:3"]PVL >/FDE8!AD$&A!!'000>XH"B
M( @" ( @" ( @" ( @" (#U-Z:?P;C?IK_\ U<GFJC+_ %$O0=[P'^60ZY?B
MD;VHQ<&3%9W4WZN"0C:1N-_&?NM0$C%A)W?K98X^H5D/@ /% 2,6'M(R"\R3
M$4-'G=;HZ"UNDCW4!*-:UH#6@-:T4  H !T #4@*H @" ( @" ( @" ( @"
MC,EJA[7^\U 12 ( @" P7_'=_./OH#Y0!#*VG)<E_N%]_G+C^T<I<?"NHYF_
M^IG]Y^LP5[/ 0$1G_P#8\M_D)_R5LM?F1^\0\_\ 17O]MGGY6QPP0! $ 0!
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M?AD>7*5T'2#T*Y/FA^I'V!P!R!SZ  !_S.ST 4'^PVW0N0\Q_J+?W/\ ,S]
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M_24F1PWB&+^HLW(KGI5=JJN\URH-=.K7U=NQ;2%4( @" ( @" ( @" ( @"
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M4#W;R3R/ROZ=\O6G*_*&*BQ6(M'/DX;7/FN;JYEIQKV_NY2Z>\O)RT;SWG4
M  T #G<C(O95UWK\JS?9Z%R'U[A7".'\$PH\/X9;5O&CR;6V]LI-ZRD^5OT4
M6AMBTED$ 0! $!4:CV?=" '6>T^^@*( @+4DT<0&^=)U-&EQUZ:= T=* Q'7
MWR(_=<?N#S0&.ZZF=]]NC8T;OCK0%@N+M+B2=I)/OH"B ("H)&HD=B P)L9C
M+F43W&.L)YQ2DTUE;2RZ-7Z1\3G&G:O2G-*B;IUFF6/CSEOSMP<^=Q3?J,Q^
MB*1HT-$4@#0*- #'4 :*  +$?$NLVO2-%LH<14PYA[0L@( @" ( @" ( @"
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M+CX:$PF8@UK.XO%>CX(#6:.Q8<V^@D0Q+$.2KZ238QD3=V-C(VC[UC6L'<T
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32 4&T>/D@*@"ATC5U[1U(#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g458540txpg3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g458540txpg3a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ C +& P$1  (1 0,1 ?_$ -,  0 !! ,! 0
M       % 08'" (#! D* 0$  04! 0$!            !0$" P0&!P@)"A
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M,6Y3M79;YWDJU\EDN*M5?0MZV^0LZD]]%3IW*C^$WIYP:V[.;=M>K+UH?/\
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M;YCR*;42G7AJD@@Z>0\: N.@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@% * 4
MH!0"@/!<KI;K/&5+NDQF''3KHIU8"G% 'L,MC5;RSIP"035T(2N.D%5F&_D6
M,:'/D24(]O3W+I,'Y+NO,E=Y$QUI4".>9)N+X29K@\BF&^TW&'43S+]%2-K#
M4?6N.K[#E,[S!<NIV\-<L.#DUKZ.HPO<WGI#,MY]UQ]YU*E.//+4XZXHD:E;
MBR5*/PUNI**I%41SDG*4G.;;D^+;J6,>D^D_+0H4H!0"@% * 4 H!0"@% *
M4 H"H)&GF.HZP>L'I% 9%QK<F\V,-QIA-VMR=$AF0X1)80-!I'DGF5H!T)7S
M#T5JW<6W<UCZLB9P=[R<.D+E;ME=#>J78S/=ARFRY&SSVV4"^E(+T)XI:ELZ
M_A,E1+B=?OD%2?/4=<L7+7MK0Z_$S\;-5;,M>IZ-%P?9\736+CJ;HH!0"@%
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M@Y$K4G2BFDZPN1_<N0<9P_=DC8NWL*C16VU#19YEK'4IS3A\"=!6R<X>R@%
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M&<4!)VD$RM=#H&U:^;70#XR* N6@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@%
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M-N?;"5$\#6E>D&QV#;J93EGB&\3>UUV%K_=C9]>RPQ!46$IBYD;@;?N9-?\
MZWF%]:9Y%R; CZ(;[IKL]KIJE-*@SQ5 * 4 H#Q.?/5Z: X4 H#$US_:,_\
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M6GWIT9GB-$9C#5M.J_*XKBKSZ=0K2.F/5K0"@% * J.@^C[8H >D^D_+0%*
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M$^V$E*B69M]G:+MK>;'BSMV&U=4YSN4M3]6<X\\I<KMJDFUJX\R+O+?FS/\
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M!MOCF.;=7^UYLWC&-W^ZVXY;N9FLS'I-PA8OAN&XTU(EN2ICC7?/AIID+<6
M"T]9\$#%/BDW2C_R_M_<EWIAI=E8YXBO"S=,&M,522$WGQ/>'>UM1]GXW=)U
M[R[Y]BF1)A)3^4=5 X?-X52YEW ]UXVHN?@ZVE_E_P"Z%SM5YR.T^&:ZY6/$
MK*L-NEW>\PF/$9ATJ+NANS(MD%I^?<8V*;BST2;DI"%NMVYQQS3E0=%?:77^
MD&SF\7C8\/=IVKOTO;G<W!MZ\]S/&[G8=J-K=K,GL^<9MN1EN16Z1:\>LUJQ
MZQ29UQCPG9TM"ITN4TS&@Q$N./J0$$53E==> -3=F(T?^7=N;A=JW]N+-@VM
MW<\+OAWVX?WFD(>5@.&;Z[$V.Z8]>\%R^_(;7#QFW9-:;T)%GF2BU$?7'6WS
MA5&^;5=8-C\H\4V.[@;U779W:S</;/<3;Z=X/M]MR,KF87?;+EUPM67V.=9;
M%C<:5>;%<YK%KAS;/>9;GNSJ.=]20M)T00;: US\!5L\&4+:/PG7F'X@67=X
MCMMMFM&#2/%GE4]A6;S<9A1G\=&TLG<-ZQJ6F;(4TW9_J[NFE@(2R"D 72;K
M3H!/8]LC-W^V\_F!X=C-S38-S+#X\LZW$V<RU&@?Q'>+ <9VXOF#W3OD$.MQ
M9<YDVZ< H<]OFO(/ Z4?%>@$KX ]Y87B.W=\76Z<> Y8KY=(_AGM6;XM)2MJ
M9AVY&*[77+&MP\/G-+2E;3UARRURF4\P',T$+Z%56225%U@^ESC2VU<JTE)\
M@/E\XZQ5@.% * 4!XG/GJ]- <* 4!B:Y_M&?_C)'ZQ5;\/97<<U?_J9][^D\
M-7F,$@ E1"4I&JE*("4CIU43P  HM=!5)5? QQE>5PE1)%KMJ_>77P&I$E&A
MCMM:_2-MK_VKBM--1V0->-;5FP^93G[*.=W/=+3MRQK#K*6C:X)?68KK>.9%
M * 4 H!0"@% * 4 H!0"@% * 4!B?>;^$&?]<@?J)M;NW_CO[+^HYGS;_:X_
MSE]V1JY4R>:GU%\ W\#[@_\ -]N_X&FN1\Q_CV_L?\Q]!?!S^T9O^YA]Q&^%
M<Z>OB@% * 4!4=!]'VQ0 ])])^6@*4 H!0"@% * T'\7.5W]O)+-B+-QDQ\?
M58&;I)M\=Q;+4^9)G36.><&RGWE##,4!M"M4)U)T).M=#M%JWX,KK2<^>FJX
M42X'COQ(W#+6=;VR,W'#\%3<4Z*4G)K7K22T7!<>)IK4L>9"@% <'?R3OZ)W
M]6JJKB6S]A]S-8%=)^#Y!4NCD'Q?>7QMSDEYQG+K%(L\]^()=WML.=&0XOW2
M?%E3&8[S$R/KW;Z2VX="1JD\00:PY%N%VRXS2TBZ/I1*;-FY6%N%J6--QYKD
M4UT--I--<'])]3%)T44C7@2 /+H"0/)YJY:E#WB6DFNTI52@J@% * 4 H#I>
M8:D)Y74A0\G6#U@](- 6]*M#J-5Q]74_[O@'!Z/O5CT:4!#E*@>4@@CI!!!'
MFT/'A0%* 4 H!0"@% * 4!)Q;8\^ M8+39'21VE<1\Q'#XS0%QQXC$8:-I[7
ME622L_\ >Z1\% ;7[9_P7;/\1<?\Z[4/E_U#[D=_L?\ ;(=\OO,ORM<EBH)!
M!!T(\M 6L,%P,+[T8'@P="^\#HPW&0X' KG#G/\ 57-W@7VN;IUX]-9_>LG_
M *MVGVY?I(K\BV'FYO<<+FK6ON]FM>NOAGY0/YM'A*ONSGB3N6Y6)66]7C;_
M ']D77-XJ[;;[E=_J#.0\RK.+!,=C,R5M-RITI%RB<Y&K$M3:?R)T]T\B;_9
MW#:(X5^48Y>+ZCJTN:&KA)<%P5'3I1^7'^4OPKSO*7Q%N^8=KLWKNQ;Y*>3'
MEC*;M9%5[S:DXJ5*SDKMNO&-QK]1F,?Y;/A&O_B)\3&+)R>QWVT[<;7/0-Q\
MYG3K;<[2F>FRW*.]CF+PY,AB*KWS(+ZTV%EM7.W#9?6"" :WO.._VMIV:YX$
MHRR[R=N%&G3F7K2Z>$:T[6CG/\=_A3N'G_XC8SW&S>M>7MLE#+R)2C.'-X<T
M[5F+:3YKMQ1JUPMQF^-#]B,G"L'ER)$J3@V$29,IUV1)D2,/QMYY]^0M3CSS
M[KEL4XZZZXLJ4I1*E*)))-?/L<G)BDE=NT2HO7EI\Y^MD]CV.Y-W;F#A2NR=
M6WCV6VWJVV[=6V]6WJR;?A0I41RWRX,&9;GF1&>MTN'&E6]Z* E(BO07VG(K
MD8)2 &U(*  !IH*P:O5ZLDDE%*,4E%)))*B26B22T2ZDM%T'&; M]RAOVZYV
M^WW*VR6TLR;;<8,6?;I+*5(6EF1 EM/0WV4*;20A:"D%((&H%"IS$."()M8@
M0?JLQ1 5:_<XQM:H 1W?U>JW%HPU0>[T3W)1W?*-.73A0$)CF'8;AR);>'X=
MB.(HGJ"YR<4QFQXX)JPKF"I@LT"%[V0KC])S:'C2K?$$G<;/9KRB,W>;-9[R
MW"E-SX2+Q:X%U1"G,Z]S.AHGQY"8DUG7L/-A+B?(H4!)<R@==3J>8$Z]*5@A
M25?A)4"0=>D'0T!:EEP3!,;N4N\XW@N$XW>9_.)UWQ[$<=L=UF!W7O1*N-KM
ML68^'2=5!2R%'II5L%Q2XD.X0Y-NN,*'<;?,;+,RWW&+'GP)C*OG,RX4MMZ+
M):/E2M"A0$#8,*PC$VY3.*83AN+-3@I,YK&L5L-@;FI7J%(F(M-OAIE(4"04
MN<R=#T4U!YXFW^WL"5'G0=OL"A38KR)$6;"PK&(<R+(;/,W)BRXUJ;D1I#:^
M*5H4E23Q!% 7+'B0XADJAPX<-4V2J;-5$BL153IKB4)=FS5,-MF7->0VD+><
MYG%!(!5P% =$.TVBW/3I%MM%IMDBZ2/>[I(MML@P)%TF'769<WX<=EVXRR5'
MZ5XK7Q/'B: ]JT(<3RK2%)ZB/M](H",?@$=IE7,!KV%?.'1\TG0'T4!&E*@2
M""".D$<10%* \3GSU>F@.% * Q/<_P!HS_\ &2/UBJWX>PNXYJ__ %,WT5?T
MEEWG*;99^9LN"7,&H]TCJ!*5:<.^>XH9 /2.*O-6>W:G<?5$B<O=,?$]7VKW
M4OK9BB[Y-=+RI29#O<QM>S#CJ4ED ='>'@IY7'I/#S5O0LPAP]KK.7RMPR<O
M23Y;?4N'_$@*S&B* 4 H!0"@% * 4 H!0"@% * 4 H!0&)]YOX09_P!<@?J)
MM;NW_CO[+^HYGS;_ &N/\Y?=D:N5,GFI]1? /_ ^X/\ S?;O^!IKD?,?X]O[
M'_,?07P<_M&;_N8?<1OA7.GKXH!0"@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@
M/G+XN_\ [)M'_)]N_P")7>NCVC^EE_,?T1/#_B1_?;?^VC]^9JO4H< * 4!P
M=_)._HG?U:JJN);/V'W,UD;9>DO(8C-.R'W5!+3##:W7G%$<$H:0"M1/F%2^
MB59:(Y*,)3FHQ3<I/2G3J; [<[-7-^\6.YY,\;6PU=;9):ML?E<N#I:FL.H$
ME?::B()3Q YG/14=EYUM0E"RFY4>O1P^<[79/*U^659OY[\.*N0?*M95YEQZ
M%])]3&XT>/S(89;;3J>(0.8\>E2SJI1/G-<HVWQX'OL+5NTN6W%)'6_%C24E
M#[+;@(TU*1S#^BH:*2:*4EP*7+-NXJ3BFBV)N//-@N0E=\@#7N5:!U/]$ZA+
M@^(^FLT;U?:(F_MTX)RL:P71T_\ $MU0*24J!2H=*5 A0](/$5GJGJN!'--.
MCXE*%!0"@% * \DF&Q)!*T +'$+3P7Z.I6GDUH"VY=M?C J [UO7YR 20/:3
MH2/3T4!'=% * 4 H  3T4![(T&1*/800@=+BN".GR$_.] H"X8MM9CE*E#O'
M!QYU '17LCB !Y">- 2= * VEVS_ (+MG^(N/^==J'R_ZA]R._V/^V6^^7WF
M7Y6N2PH!0'(+4D: Z G73R:CH.G137M'9T K4H:$\.G3H&O7H*=X[."[-#C0
M"@% * 4 H!0"@% * 4 H!0"@% =+K#3PT6D:^10X*'H- 13T)UO52?I$:^0=
MH#3RIU)/P4!"N?/7YE:'S'JH#A0'8VTMPZ)'PG@/CH#43.\KN;E^OEKCJ$./
M%N<V(M3"CW[Y9?<0I2GNR4(7^"GR=)-3V-8BK<9RU;2?<>7;QN>1+,NX]I\E
MN-R2=.+H^)C3I.IXD\23TDGI.OGK;22X'/\ :*J!0"@% * 4 H!0"@% * 4
MH!0"@% * 4!B?>;^$&?]<@?J)M;NW_CO[+^HYGS;_:X_SE]V1JY4R>:GU%\
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M/_-]N_X&FN1\Q_CV_L?\Q]!?!S^T9O\ N8_<1OA7.GKXH!0"@% 5'0?1]L4
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M6V=-%",SJ6XX/6-5^>M.Y>G<T>B.IP]LQ\1J:7-=7ZSZ.[J+LK$2 H!0"@%
M* H0% I4 I)&A2>((ZB#P(IPX!ZJCU1;\['VGM5PU".LZZM'532O+V3\YM7H
MU%9H7FM):HC;VW0E65CU9=70_P!!:C\:1%66I#2VU#70J&J5#7[U?0H5L)J6
MJ9$7+=RU+EN)IG30L% * 4 H!0"@% * 4 H#YP[@IV(O?CR_=_QX3H36QD38
MNUS_  YV[<&Y7.S[02\HD3F?W]ESI$5^' >R)N;[XV"^Z %(:2KHC@]IAK<[
M?E=W/+";W-Y+5]PH[JBDN6E:Z4HW1/BZ:U/FSS'_ .$YOQTEM_QLN17DN&S0
MEM,<F=RW@NZY+WERE%QB[O,[B]:7%13X01]2/#AEGA8P7PTW'*?#M=H#GAXV
MX=W+N[D^-/O4R%%<QJ;<[WEJ(T_)UFY/04.H5[FI2RR8JF>Z)1RUQ6[X^]96
M\1L;K%_FE[PU337F24=(KBZKFZ:UKP9](_#[=/ACL7PYN;GY NVWY!VYYD^=
M2N.,?!<[M]<U[UVDU2#;<>1P4=&CXF>!K>+*L3\7.V&^&<XMNAC$'QT7/<^Q
M9OE&8X^_:-N<BO\ D>1/91LNG;Z_R5EF^-6JV1F8+O9;Y"[]'SH.H]'\S;?8
MO[!>V[&G9G+;E;<(P=;D8QBH7>==%=9=O32A\;_!3S;NFU_%;;_.6]8NY8UK
MSI<S+61>R+4H8EV[>NN]@>ZW&^6YR+EM<(TYJ1YDZFVO\U/!\WW$\1G@-Q+;
M"_C%]T)4C>Z[;=7DK#1CYIBEKQG*L>C+<YD\C-SN=E;B+4=4I2_V@4\PJ"\C
MY&-B;1N>1F1Y\->$KB_<ES1E\B=?0>H_Y/;-O._?$+R1MOEN^\?S(_S&YBSK
M2E^Q"S?M*O%*<[:@W6FNM55$_P#RH=R[GO#N;XZMR\CQYW$,DRS=3;B;EF,2
M=42+#D\3%KO:LEMCK:P'6?=KY D!"%@+0G1*NT#6#SUAV]OP]MPK,_$M0L3Y
M9+]:+G%Q?R-$C_BYYBR?-OF#SKYAW#'>+N&3N6)*]9EQMWHVKD+T*:-)78S2
M3U7!ZU->[1&\'V4>)7QS#^93<K(QN;9MP)D/;:%N??<ALUHM6QC<![]UY.TR
M+=*BI7<G8O<N(,0+D+*D*:2I:GB9>X]_L;3MK\H*3PY6D[C@HMN]77Q:IZ+A
M1TX,X'#M?"C=/B'YTC_D-<M1\R6L^4,2.7=O6X1VY)^"\+DE&MQJC2A63K&4
M8N3D;^>+^9M]-_E<[L3-JY E;8.^'>Q_N#(*YKBG<2:?QQFR+=<NO_N*I0B-
MI#AD?3%T'G[6M<IL,<J'G2RLU4S?>I<ZTISTES<-*5ZM.H]W^*][8\C_ !KW
M.[Y7DI>7);%:]U=9.MCFM*W5S]=RY:5Y_6K52UJ8M_E4VS;"VXIDJ\<B>$^%
MGD_"]NGKJCPYY7D.09=+QM%N*UR=X8-]G26K3D@O[WTB(B$,"6IY/0$BI#SQ
M+-E>AXWO[Q5<N)>\048\U=/"HE6/+P;UI0YC_&#'\MV-LR7@1\L0WN>'B.:V
MJ_=NWG9Y6^;/C<E*-N]XKHU;I%3YUT)'R>\:F-JN'B-_F"Y"=M<>N%NLV]>P
MEJNN_P#)O%V8R7PY)R"+:6VLGL]@LSS,B[V^^B&N/,>5JF*4- ?2.(-=SY=O
MJ&T;59\:2<L:\U825,CEK6+E*JC2M:+CW5/EGXP[;+(^(7GK._+K$[%K>=MA
M/<W<FKVUJ[RI7;=FVT[L;CBXSD_8:C3UI(_5QC?<?NUC9C7M.2QCCUC]WR1#
MK;R<B83:X@:OP>:4MMT7E $GF"B#WNNIKPR\I*[/FCR2YY5C^RZOU:=G _47
M;G#\OQU;OK)@L>U2]5/Q5R*EVJJGXB7/5/7F/GM_-*V;VJSCPE[R[G9A@]CO
MV?;5[97E[;S++@F2+IB+EPO=D5+7:UM2F8Z?>' "KO&W./176>2MQS<;?,?$
MQ[DH8UZZO$BN$J1EQ?'3HX'@G^3'D_RUO?POW;S%NN%:O[[MN!-XUZ7-S6>:
M[;KRI/E;;?2F^CAH9H\".S6U6U.P&U%WVUP>Q8=<-R]N-K,JSN99DR@YE.1G
M%(+AO-S]XERDJE+7/>5JV$()=5H.BHWS/N.=G[K?MYER5R-F_=A!/]6/-P7R
M+Y#L/@CY1\L>6/(FUY?E["L8E_<=NPKV3*WS?QKG@1?/*LI:UG)Z459-TU/S
MR3)WB$1_+>\2D2U639]SPW+\2>6JR2_3;SD#>[4?)/\ J?C!2S:K.RPK&GK2
M9Z8:>9UP.=TMTZ:I37K,8[3+S?B.4K_YO[I%*-(NUR\DGJZ\W-[7#3@? F3>
M\_Q_Q[\P6;&/M7_UX]_N^+<E<NK.C=659:4+=/"<&_#2;=>7FIT'VB_F9E _
MEG[G\QY4_N3LUJ> X'+\! T)T3Q/17G?DRO_ )C9;X^+>?\ ^,S[ _R/<?\
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M4XXLZ:Z)0D%1]/15KDH\>!?"$[DE&";D^"6IDRS[;/OH#UZDJAZ@$1(I;6^
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M&U:+DJ2?*OL^S6M<RYS?+#2-?236%Y?L8\?%RWXMVG#]5/LZR$ "0$I 2E(
M2E("4I X )2D ) 'DK)6I@HH^K'V4*J!0"@% * 4 H!0"J ZW66GT=V^VEUO
M\%0U'I!Z4GSCC54W'V2V<(7(\LU6):\W'E)U<@K*T\=8[A[?7]&X>"_,#H?.
M:SQO=$B*O[:UZUAMKJ9;:T.-J*'$*;6G@4K!2H'S@CJK.FFJK@1;C*+I)49Q
MH4% * 4 H!0"@% * SU8<#P7<';NRVC/L)Q#.;7%G7*3&MV88U9LEAQ9)F.A
M4B+'O,*8W&>6$@*4@)*@!J=*C[F7E8N5*>+=N6IM)-QE*+:[:-5[*G56MAV/
MS!LMK&W["Q,W'C.4E&_:MW8I\SU2N1DD^U4,DG%,3_=M>&C%L<&'.VY=H=Q)
M-CM:,8<M3J2EVVKL"8HM2K>ZDZ*9+1;7J=0=:U/'O^/[SXD_>:UYZMRKUU>M
M>VI./:=J>VO9_=<?\I=MVW8\.'@N#XP\/EY.5]*Y:/J/+,P;![A;,>LMPPO$
MYUGQ&3 FXE:9F.V>3;,5F6ML,VR9C<!Z&N-8Y5N:'*PY%2TIE/!) JZ.5DPG
M.["Y-7+BI)IOUD^*D^GTF*]LFRY&/CX>1AXMS$Q)1E8A*U!QLRAI"5F+BU;E
M'A%PI1<*'LN6,8S>+O9,@O&.6&[7_&7);N-7VY6BWSKSCKL]"6I[MBN<J.[-
MM+DUI 2ZJ.MLN) "M15L+]^W;E9MSE&S/VHIZ2IPJNGTF?(VS;<O,L;CE8]B
M[N&,Y.S<G"$IVG)4D[<Y)R@Y+23BU5<2EHQ7%L?GWVZV#&<?L=TRF:FYY-<;
M/9;;:YV1W-(6!<K],@QH\B[SQWJ_II"G'.T>/$TN7[]Z$;=Z<IP@J1JV^5=2
MZEV(MQ-JVO NWLC QL>QDY,^>]*W;C"5V>OKW'%)SEJ_6E5ZO74A<KVQVSSR
M9;;CG6W.!YK<;. +3<,MP_'LCG6Q*5]XE$&7=[=,D1FD.'F"4*"0HZZ5EL9V
M;BQ<,:]=MPEQ49R2?>E])I;KY8\M;[?MY.^;=@YF1:HH2OX]J[*"3JE&4XMI
M)ZTK2I<5UL-AOMGEX[>['9[SCL^*F!.Q^ZVN#<+',@I*"B%*M,MAV _#06DZ
M-*;*!RC0<!6&%V[:N*]9E*%U.JDFTT^M/BF267@X.?B3V_.LVKV!<CRRMSA&
M5N4>B+MR3@TJ*BI145%H6YB>V.VF R9LS ]N\%PF7<F&HMQE8CB./XW)N$9E
MPO,QIK]FM\)V4PT\2M*%E20HZCC67(S<S+265=N7(K@I2<J=NKXD=M7EKRYL
M5R=[8]OP<*]<BHSE8L6[+E%.JC)PBFTGJJOB>F1M[M_,.5JF8+ADLYXB.WG)
MDXM8WSFB(@2F(C+2]!7^\:8J4 -^^=]R:#ETTHLO*BH*-VXE:]CUGZE>/+KI
M7L,ESR_L%UY+NX.')YM/>:V;;]XY?9\>L7XO+T<_-3H+CMUNMUGMT&TVBWPK
M5:[9%9@VZV6V*S"M]OA1D!J-#@PXR&X\6+':2$H;0E*$)&@ %:\I3G-SN-RF
MW5M\6^MDCC8V/AX\,3$A&UB6HJ,(02C"$5HHQBDE%+@DDDEHD=-YLMER.U3[
M#D5GM=_L=UCF)<[+>H$6Z6FY15*2M4:?;IS3\29'4I )0XA220#IPJZW<N6;
MBNV92A<7!Q=&NYEF9A8>XXL\'<+-J_A752=NY&,X375*,DXM<-&FCU0(<*U0
MX-MM4.+;+=;(S$.W6^WQV8<*WPXK:6HL2#$CI;8BQHS2 AMM"4I0D   "J3E
M*Y-W+C;G)U;Z^WO,EBS9Q;,,;&A&WCVXJ,(Q7+&,8JB48K2*2T26B7 M'_IG
MMK^[=PPT;=X+^YUWN#EUNV)_NE8!C5TNCTAJ8[<[A8O</JR;<'9;"'5/.-*<
M4XA*B>8 UL>^Y?BK(\6Y[S%44^9\R74G6J5"+_\ &_+GY=<V?W#"_*;MSGG9
M\"UX4IMJ3G*WR\DI.23<G%RJDZZ$Y>\:QK)K(_C628]8\AQN2U&8DX]?+1;[
MM8Y#,)UEZ&R_:9\=^ ZU$=CMK;2ILAM2$E.A2-,5N_>LW?'LRE"ZOUDVG5\7
M5.NO8;N=MNV[EARV[<<>SD;?)13M7(1G::C3E7AR3BTJ)I-432:X$1B6W6W>
M >_' \!PK!S=.X%S.'XM8\:^L?=>\]U]_P#J:##]]]V[Y?=]YS<G,=--363(
MS,S+I[U=N7%'AS2<J=W,VS3VGR]Y?V#G_(<##P?%IS^[V;=GGY:TYO#C'FI5
MTK6E73B<).VVVTR'E%NF;>8-+M^<3FKIFL"5B5@D0LPNC#@>8N>417K>MF_W
M!EY(4AZ4EUQ*@"% BJK-S%*$XWKBG;5(4D_475'71=:1;/RUY<NVLG'N[?A3
MQ\R:GD1=FVXWYIU4KR<6KDD]5*?,T2-QPW#KPQC\:[8EC5TCXE,AW'%8]RL5
MKGL8S<+:RF/;I^/M2XKJ+--@,("&78X;6T@ )( TJR&3D6^?P[DX^(O6:;3D
MGJT^M-ZNIL9&S[1EV\>UEXF-=AB34["G;A)6915(2M)Q:A*"2491HXK1-'>K
M&,97DHS16.6%69"UFQC+56>W')Q9"[W_ -3?7QC?6AM7?GG]W[WN>;CRZU9X
MU[P?=N>7NU:\E7RUZZ<*]I>]KVV6Y?G4L>Q^<>'X?C^'#QO#K7P_%IS\E=>3
MFY:ZT*PL9QJVWJ\Y);L>L5OR/(D0FLAR&%:($2^7]NVM=Q;D7J[,,(GW1$!G
ML,A]QP-)X)T%5G?O3M1L3G)V85Y8MZ1KQHN"KV%UG;-MQ\R]N./CV+>XY'+X
MMV,(1N75%4CXDTE*?*M(\S=%HB8=::?:=8?;;>8?:=8?8>0EUE]AYM33S+S:
MP4.-.MK*5)((4#H>%8TVG5:-&W.$+D';N)2A)4:>J:>C33XIK1KI1$X_CF.X
ME:(F/XI8++C%A@!T0;'CUK@V6SP@^ZN0\(=LMK$:%&#K[BEJY$)YEJ)/$DU?
M=O7K]QW;\Y3NOC*3JWWMFK@;?@;5B0P-KL6<;!MUY;=J$;=N-75\L()1575N
MBU>I,UC-PJ.GX#\AH"">_*N_I%_C&@/*_(CQ6^]E/LQF]2.=]U#2#IIT*6H
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MR8X1'O"%3&1HD2VP!*0.MQ)(0^!_W5>FM>YCJ7L:/YB:Q=XN0]3)7-'KZ?\
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M$=!' T!-6^4MQ19<)4>4J0H].@(!23Y>F@):@% * J.@^C[8H >D^D_+0%*
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M)E!ONI#++CP<:[(<+:"K1Q'S5:A/3TU?";3H:.9B6;D)74DKB5:HQG6R<\N
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@7U?A4!/]CVO50#L>UZJ =CVO50%1R:'YW1YNL4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g458540txpg3b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g458540txpg3b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ .@+& P$1  (1 0,1 ?_$ ,H  0 !!0$! 0$
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M6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT
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ME0O;9]Z.Z^A,HKCTWQJEIH5O%7-.47L;P[3G]RI]O;/B;D=J*1@)&MDJ;BZ
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M%2"G3:<'DUD7%@]! $ 0&UV8849)W97X<.&KS>! 2J ( @" ( @" ( @" (
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MD2R\&\("4M/TD_%N_*$!LB ("IN9_HCW[4!2@" ( @" ( @" (#Z 2< "3O
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MA98!L9:3++)(=.NQ:T!C3_GJ@9\7.P\"J+OSY?3D.^X%^F0Z9?FD=*CH:2+
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M02 X%E933TSL=X:YC [O8J5&<9K&+3125:%>@]VO"<)?O)KVF&O1J" ( @"
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MFGW,M7QE?_'U*I[OSW].1'?<"_3*?7^:1O:CEN$ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $!3(]D4;I9GLAB;E=+*]L431ONDD+6-'=*+3H69B345O2T17*S0;
MSVJ]GU@<YM=M-033QXXTEL<^Z5)(')#:%LT;7>DYJE4[*YJ]V#PY]'M*:Z]0
M\%M&XU;B#FN2/VW_ *<5M9JE5VG4$S6SVVVU4S:A@GB=7.;2>1,-8S2A9KI
M=%V48A9_XLD\)-=1K?'J,H*="$FI)-;VC/3EI9K%5M]M#.3JI*:C9EP;3T['
M.&._)4:YQP[RV*WI<N+(-3C%Y/NN,%S+WO$Q(]M-I6.TO:1DS>3+3TKFG-D(
M$(SKUX-+## UKBE\OOX]2^HGZ/M(KF8-K[?35(R8R4SWTTF&[Y#M=&3S5K=M
M'[K:)E+C=6*PK0C+G3P^LVNBV\L%5@)I*B@><,14PET8W_A8#(/" M,K>HLL
M&6%+C%G4[SE!\Z]ZQ-D94VN[PEC)J"YP.&6(FGJV$'/I0OT\.^%JPG!\J9.4
M[>YC@G"I!\FA]AI]U[+MA[KIF6QQ4,SSB9K5)+;W@[^JB)IMW=C*WPN[B&4F
M^G25EQZ?X1<Z945">N#W>Q:.PYO=.P.G=I/LFT$L60EM/=:5LS<=P>M4AC<
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M+S'H^%5\.OJ.ON_+7E9?>SZCFLO+=T>?]3T?Z/ I*R.?EWGEGR9=1;63 0!
M7:;IV=/RA]%^D;G1^=O+#R/4.^L^K/J.[;+_ $5OWCY/^\]%^R4"KWON]1UM
MAY?]?^/W&UK26(0$1M%]FR?8/(=]Y_L[-^5;*7>^]_#F1;[R'Y/^[W#Q+M;]
MJ3?=;EN^ZWT//N\*OZ/=^_\ Q'RCB/S#^7S?D]TU9;RO" ( @ SK#R,K,[UV
M=?=MO1_3ZOH^5RF]+YWYOFX*JO?.Y?=U':\!_3E^.7MY?=S&]#..[NYN^H9<
M&U6CDC[+_1^D[GC7B63SS+.TR_I]69LIS[O?SK46!\0! $!6S/WO[P@+J (
<@).V=.[XIV;TV<K^Y 3J ( @*FYG^B/?M0'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
